Drug Eluting Stents Market, by Drug (Sirolimus, Paclitaxel, Zotarolimus, Everolimus, Biolimus, and Others), by Coating Type (Polymer-based Coatings and Polymer-free Coatings), by Application (Coronary Artery Disease and Peripheral Artery Disease), by End User (Cardiology Centers, Ambulatory Surgery Centers (ASCs), and Hospitals), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa)- Size, Share, Outlook, and Opportunity Analysis, 2022 - 2030
Stents are usually used in the treatment of coronary angioplasty or percutaneous coronary intervention producers. The types of drug eluting stents include bare metal coronary artery stents, coronary artery restenosis, coronary artery stents, coronary revascularization, and others. Coronary artery stents are small cylindrical device that helps in improving blood flow through arteries to the heart by reducing blockages in the artery. Coronary artery stents are more beneficial for patients suffering from coronary artery diseases such as myocardial infarction.
Market Dynamics
Different Manufacturers like Boston Scientific., Medtronic, and others are focused on developing and launching new products and receiving product approvals from the United States Food and Drug Administration (U.S.FDA). For instance, in April 2019, Shanghai-based medical company MicroPort Medical (Group) Co., Ltd. received the U.S.FDA approval and CE (Conformité Européenne) Mark for ‘Firehawk Liberty’, a new generation rapamycin target eluting coronary stent system.
Furthermore, in May 2022, key players such as Medtronic, a global medical technology company, obtained the U.S. Food and Drug Administration (FDA) approval for Onyx Frontier drug-elution stent (DES), used to treat blockage of the heart arteries. It has enhanced delivering system and increased acute performance which is used to treat patients suffering from coronary artery disease. Onyx Frontier provides 4.50-5.00 mm sizes that can be expanded to 6.00 mm. It is specifically, designed to support extra-large vessels, while it shares the clinical indications as Resolute Onyx, including the most recent approval for patients that are at high risk of bleeding and may benefit from a dual anti-platelet therapy (DAPT) duration.
Moreover, an increase in the awareness of cardiovascular diseases such as heart failure and coronary heart disease cases globally is expected to fuel the global drug eluting stents market growth over the forecast period. For instance, in January 2020, according to the data published by the American Heart Association (AHA), the awareness of coronary artery disease is higher in females (54.4%) than males (45.6%). The mortality rate is also higher in females than in males with myocardial infarction (a dangerous condition caused by a lack of blood flow to the heart muscle).
Key features of the study:
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook